Ruetsch Caroline, Brglez Vesna, Crémoni Marion, Zorzi Kévin, Fernandez Céline, Boyer-Suavet Sonia, Benzaken Sylvia, Demonchy Elisa, Risso Karine, Courjon Johan, Cua Eric, Ichai Carole, Dellamonica Jean, Passeron Thierry, Seitz-Polski Barbara
Laboratoire d'Immunologie, Centre Hospitalier Universitaire (CHU) de Nice, Université Côte d'Azur, Nice, France.
Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Université Côte d'Azur, Nice, France.
Front Med (Lausanne). 2021 Jan 27;7:603961. doi: 10.3389/fmed.2020.603961. eCollection 2020.
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged in Wuhan in December 2019 and has since spread across the world. Even though the majority of patients remain completely asymptomatic, some develop severe systemic complications. In this prospective study we compared the immunological profile of 101 COVID-19 patients with either mild, moderate or severe form of the disease according to the WHO classification, as well as of 50 healthy subjects, in order to identify functional immune factors independently associated with severe forms of COVID-19. Plasma cytokine levels, and cytokine levels upon non-specific stimulation of innate and adaptive immune cells, were measured at several time points during the course of the disease. As described previously, inflammatory cytokines IL1β, IL6, IL8, and TNFα associated with cytokine storm were significantly increased in the plasma of moderate and severe COVID-19 patients ( < 0.0001 for all cytokines). During follow-up, plasma IL6 levels decreased between the moment of admission to the hospital and at the last observation carried forward for patients with favorable outcome ( = 0.02148). After stimulation of immune cells from COVID-19 patients, reduced levels of both type I and type II interferons (IFNs) upon stimulation were correlated with increased disease severity [type I IFN (IFNα): > 0.0001 mild vs. moderate and severe; type II IFN (IFNγ): = 0.0002 mild vs. moderate and < 0.0001 mild vs. severe] suggesting a functional exhaustion of IFNs production. Stimulated IFNα levels lower than 2.1 pg/ml and IFNγ levels lower than 15 IU/mL at admission to the hospital were associated with more complications during hospitalization ( = 0.0098 and =0.0002, respectively). A low IFNγ level was also confirmed by multivariable analysis [ = 0.0349 OR = 0.98 (0.962; 0.999)] as an independent factor of complications. treatment with type IFNα restored type IFNγ secretion in COVID-19 patients while the secretion of pro-inflammatory cytokines IL6 and IL1β remained stable or decreased, respectively. These results (a) demonstrate a functional exhaustion of both innate and adaptive immune response in severe forms of COVID-19; (b) identify IFNα and IFNγ as new potential biomarkers of severity; and (c) highlight the importance of targeting IFNs when considering COVID-19 treatment in order to re-establish a normal balance between inflammatory and Th1 effector cytokines.
2019年12月,武汉出现了由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的2019冠状病毒病(COVID-19),此后已蔓延至全球。尽管大多数患者完全无症状,但仍有一些患者出现严重的全身并发症。在这项前瞻性研究中,我们根据世界卫生组织的分类,比较了101例轻度、中度或重度COVID-19患者以及50名健康受试者的免疫特征,以确定与COVID-19严重形式独立相关的功能性免疫因子。在疾病过程中的几个时间点测量了血浆细胞因子水平,以及先天和适应性免疫细胞非特异性刺激后的细胞因子水平。如先前所述,与细胞因子风暴相关的炎性细胞因子IL1β、IL6、IL8和TNFα在中度和重度COVID-19患者的血浆中显著升高(所有细胞因子均<0.0001)。在随访期间,预后良好的患者从入院到最后一次随访时血浆IL6水平下降(=0.02148)。刺激COVID-19患者的免疫细胞后,刺激后I型和II型干扰素(IFN)水平降低与疾病严重程度增加相关[I型IFN(IFNα):轻度与中度和重度相比,>0.0001;II型IFN(IFNγ):轻度与中度相比,=0.0002,轻度与重度相比,<0.0001],提示IFN产生功能耗竭。入院时刺激的IFNα水平低于2.1 pg/ml和IFNγ水平低于15 IU/mL与住院期间更多并发症相关(分别为=0.0098和=0.0002)。多变量分析也证实低IFNγ水平[=0.0349,OR=0.98(0.962;0.999)]是并发症的独立因素。用I型IFNα治疗可恢复COVID-19患者II型IFNγ的分泌,而促炎细胞因子IL6和IL1β的分泌分别保持稳定或下降。这些结果(a)表明严重形式的COVID-19中先天和适应性免疫反应均存在功能耗竭;(b)将IFNα和IFNγ确定为严重程度的新潜在生物标志物;(c)强调在考虑COVID-19治疗时靶向IFN的重要性,以便重新建立炎症和Th1效应细胞因子之间的正常平衡。